Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Platform Revolutionizing Cancer Treatment

Posted on December 4, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven, precision-medicine company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. An article discussing the company reads, “POAI’s platform, composed of over 150,000 patient tumors, harnesses the power of an … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Posted on November 25, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $15 Million Equity Line

Posted on November 20, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC, a Puerto Rico limited liability … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development

Posted on November 19, 2019 by MissionIR

Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer Tremendous unmet need for patient-derived tumors (PDx) for new drug development – current mouse models unreliable TumorGenesis unique in the industry; its ovarian-cancer cells haven’t … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Corporate, Scientific Milestones in NetworkNewsAudio Interview

Posted on November 19, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, this morning announced the broadcast of a NetworkNewsAudio … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reports Q3 Results, 58% Revenue Increase

Posted on November 18, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, on Friday announced its financial results for the … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Harnessing the Power of Artificial Intelligence to Improve Clinical Outcomes

Posted on November 15, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients. An article discussing the company … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc.’s (NASDAQ: POAI) AI-Driven Predictive Models Better Inform Clinicians, Researchers; Changing Landscape of Cancer Treatment

Posted on November 13, 2019 by MissionIR

POAI subsidiary Helomics announce sequencing of ovarian tumor cases from UPMC Magee collaboration, a critical step in strategic Cancer Quest 2020 initiative Data key to value in $48-billion precision-medicine industry Industry leaders such as POAI realize critical value in patient-specific, … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Extensive Database, Artificial Intelligence to Identify Applicable Cancer Treatments

Posted on November 8, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting the most effective drug treatments … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Officer Presents Initial Findings from Analysis of Landmark UK 100,000 Genomes Project

Posted on November 8, 2019 by MissionIR

Helomics chief technology officer speaks at inaugural UK 100,000 Genomes Project Conference The 100,000 Genomes Project is a UK-government project, sequenced whole genomes from National Health Service patients The depth of the project data is best in class, yielding useful … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment